Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$2.17 USD
-0.06 (-2.69%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.18 +0.01 (0.46%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Corvus Pharmaceuticals, Inc. [CRVS]
Reports for Purchase
Showing records 101 - 120 ( 154 total )
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE-The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ITK Inhibitor CPI-818 Shows Activity Against Malignant T-cells
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SITC 2019 Event Highlights Adenosine Signature Biomarker
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Adenosine Pathway Blockade and Anti-PD-1 Combo May Hold Promise
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - SITC 2019 Abstract Title Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 - Data Incoming at SITC. Blocking CD73 Blocking Could Be Key.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SITC Is Only 33 Days Away: Abstract Titles Released
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2019 PacGrow Healthcare Conference: Day 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Multiple Program Updates Expected at SITC
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Update - Momentum Continues to Build - SITC Should Be Material
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T